Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222973 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT03222973 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 263 participants.
The verdict
NCT03222973, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS. The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.
Interventions
- DRUG Placebo
- DRUG BIIB033 (opicinumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2021-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222973
The ClinicalTrials.gov registry entry for NCT03222973 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03222973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03222973 about?
NCT03222973 is a clinical study titled "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)". The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS. The secondar...
What is the current status of trial NCT03222973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2017-11-15. Estimated completion is 2021-02-12.
What interventions are being tested in trial NCT03222973?
The interventions under investigation include: Placebo (DRUG), BIIB033 (opicinumab) (DRUG).
Who is sponsoring clinical trial NCT03222973?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.